Neurophet raises $28M Series D for US commercial launch of AI brain MRI platform
Summary
Seoul-based Neurophet secured ₩37B ($28M) Series D led by IMM Investment with LB Investment and Samsung Fire & Marine Insurance, ahead of their US commercial launch of NEUROPHET AQUA. The company has received FDA 510(k) clearance for automated brain volumetrics and is pursuing a second clearance for Alzheimer's disease biomarker quantification from standard clinical MRI.
Why it matters
Two FDA clearances and a $28M Series D positions Neurophet for a US direct sales launch in the large academic radiology and neurology market. Korean medical AI companies have struggled historically with US commercialization — this well-capitalized push with Korean conglomerate backing changes the probability of success.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial